BlackBerry Hits New 52-Week High on QNX Momentum and Buyback
Markets Daniel Marsh

BlackBerry Hits New 52-Week High on QNX Momentum and Buyback

BlackBerry shares hit a 52-week high of $10.26, up 4.2%, on QNX robotics momentum, FedRAMP recertification, and a renewed buyback. The stock's $2.1B market cap jump faces a key test at June 25 earnings.

BB
Grab Stock Flat as Investors Eye Digital Banking Expansion
Earnings James Calloway

Grab Stock Flat as Investors Eye Digital Banking Expansion

Grab Holdings shares barely moved as Q1 results impressed with 24% revenue growth, but unchanged full-year guidance and risks tied to its Superbank consolidation kept investors on edge.

GRAB
Bitmine Stock Tumbles as $11.6B Ether Bet Sours on Crypto Slide
Crypto Sarah Chen

Bitmine Stock Tumbles as $11.6B Ether Bet Sours on Crypto Slide

Bitmine shares slid 6.5% to $17.62 after revealing 5.42 million ETH holdings, with a $502 million paper loss as ether dropped 4%, highlighting the stock's direct exposure to crypto volatility.

BMNR
GPUS Surges 46% on Bitcoin Treasury and Buyback News
Markets Daniel Marsh

GPUS Surges 46% on Bitcoin Treasury and Buyback News

Hyperscale Data Inc. shares soared 46% after a $5M buyback and Bitcoin treasury update, but a filing warns of up to 43M new shares from convertible notes.

GPUS
Cisco Surges 5% on AI Security Platform and Raised Orders Target
Technology Sarah Chen

Cisco Surges 5% on AI Security Platform and Raised Orders Target

Cisco shares surged over 5% on Tuesday after the company launched Cloud Control, an AI-driven IT security platform, and raised its fiscal 2026 AI order target to $9 billion.

CSCO HPE MRVL MSFT GOOGL AMZN NVDA
Oklo Stock Surges on Nuclear Fuel Hopes and DOE Milestones
Markets Daniel Marsh

Oklo Stock Surges on Nuclear Fuel Hopes and DOE Milestones

Oklo shares surged 8% amid DOE plutonium fuel talks and a July reactor pilot deadline, as investors eye advanced nuclear growth from AI and data centers.

OKLO SMR META NUE
IREN Shares Jump on $3.65B Debt Deal for Microsoft AI Cloud Contract
Technology Sarah Chen

IREN Shares Jump on $3.65B Debt Deal for Microsoft AI Cloud Contract

IREN Limited shares climbed 3.8% after closing a $3.65 billion debt deal to fund GPU purchases for its $9.7 billion Microsoft AI cloud contract, covering 96% of capital needs.

IREN MSFT NVDA DELL QQQ
Keel Infrastructure Breaks $6 as AI Power Push Intensifies
Markets Daniel Marsh

Keel Infrastructure Breaks $6 as AI Power Push Intensifies

Keel Infrastructure Corp. (KEEL) jumps 2.29% to $6.24 on heavy volume, driven by its pivot to AI data-center power and a 2.2 GW pipeline, despite Q1 revenue drop and net loss.

Milbank Sets New Big Law Salary Benchmark at $455K; Rivals Quickly Follow
Analysis Daniel Marsh

Milbank Sets New Big Law Salary Benchmark at $455K; Rivals Quickly Follow

Milbank LLP has increased associate pay to $455,000, prompting immediate responses from rivals like McDermott Will & Schulte and reigniting salary competition among top U.S. law firms.

FuelCell Energy Shares Jump 14% Ahead of Earnings, Options Signal Big Swing
Markets Daniel Marsh

FuelCell Energy Shares Jump 14% Ahead of Earnings, Options Signal Big Swing

FuelCell Energy shares jumped 14% to $24.31 ahead of June 8 earnings, with options pricing a 17% swing. The rally is fueled by AI data-center power demand, but a 10.8% backlog drop and ongoing losses add risk.

FCEL BE PLUG
Laser Photonics Jumps 121% on Anti-Drone System's Defense Review Selection
Technology Sarah Chen

Laser Photonics Jumps 121% on Anti-Drone System's Defense Review Selection

Laser Photonics shares surged 121% after its anti-drone system was selected for a key U.S. defense technical review, but no contract or sales were announced, and the company faces a Nasdaq compliance notice.

LASE
Legend Biotech Surges on Promising Early In Vivo CAR-T Data
Technology Sarah Chen

Legend Biotech Surges on Promising Early In Vivo CAR-T Data

Legend Biotech shares soared over 35% after early Phase 1 data showed all six high-dose patients with relapsed/refractory B-cell NHL responded to its in vivo CAR-T drug LB2501, with five complete responses and no relapses as of April 1.

JNJ